About
Revagenix develops precision-engineered inhaled medicines targeting serious chronic respiratory diseases, with its lead program Rev-56 focused on non-CF bronchiectasis, entering Phase 1 clinical development in 2026.
Explore Revagenix's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.